Page 4 - Solid Biosciences News Today

On November 29, Annie and Ilan Ganot P’26, co-founders of Solid Biosciences, a Boston-based biotechnology company, gave an inspiring presentation to the CA community. They shared how they are developing treatments for Duchenne muscular dystrophy, a progressive and life-limiting muscle-wasting disease that afflicts approximately 10,000 boys in the United States alone, including their son. The Ganots shared how they leveraged their expertise, networks, and unrelenting drive as parents and profes...

Solid Biosciences (NASDAQ:SLDB – Get Free Report) and Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. Profitability This table compares Solid Biosciences […]

By Denny Jacob Getty Images Holdings lowered its 2023 outlook, citing challenges ranging from strikes in Hollywood to a stronger dollar. Shares retreat 5.8%...

Shares of Solid Biosciences Inc. (SLDB) are up 27% on Wednesday following the announcement of FDA clearance of its Investigational New Drug (IND) application for SGT-003, which is the company's latest gene therapy candidate for Duchenne Muscular Dystrophy (Duchenne).

Solid Biosciences Inc.

It wasn’t dismal news for sufferers of Duchenne Muscular Dystrophy (DMD). It does appear that Elevidys can slow the disease's progression.

By Stephen Nakrosis Shares of Solid Biosciences were trading higher in Tuesday's after-hours market, following news the U.S. Food and Drug Administration...

Solid Biosciences Inc. (NASDAQ:SLDB – Get Free Report) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 21,500 shares, a decrease of 27.4% from the September 30th total of 29,600 shares. Based on an average trading volume of 23,700 shares, […]

/PRNewswire/ -- DelveInsights Pompe Disease Market Insights report includes a comprehensive understanding of current treatment practices, Pompe disease...

Joe Lewis must wait until at least January for his next court hearing for allegedly “orchestrating a brazen insider trading scheme” that involved passing non-public information to his girlfriend and two private pilots. The British billionaire, who founded Tottenham Hotspur’s controlling company ENIC Sports Inc, was indicted in July. He pleaded not guilty to all 16 counts of securities fraud in a Manhattan federal court on July 25 and his bail was set at $300million, secured against his 98...